Skip to Content

Positive results presented by the VISION trial

Addition of 177Lu-PSMA-617 to the standard treatment significantly improved radiographic progression-free survival versus standard treatment by 5.3 months with a significant reduction and the risk of progression or death.

Man at the doctor

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top